X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Procter & Gamble Health with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs UNICHEM LAB - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH UNICHEM LAB PROCTER & GAMBLE HEALTH/
UNICHEM LAB
 
P/E (TTM) x 48.9 55.6 87.9% View Chart
P/BV x 4.4 0.6 740.4% View Chart
Dividend Yield % 10.7 2.3 462.6%  

Financials

 PROCTER & GAMBLE HEALTH   UNICHEM LAB
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
UNICHEM LAB
Mar-19
PROCTER & GAMBLE HEALTH/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs3,549292 1,215.4%   
Low Rs1,301182 715.0%   
Sales per share (Unadj.) Rs511.4167.7 305.0%  
Earnings per share (Unadj.) Rs61.3-3.6 -1,688.1%  
Cash flow per share (Unadj.) Rs74.05.9 1,245.7%  
Dividends per share (Unadj.) Rs440.004.00 11,000.0%  
Dividend yield (eoy) %18.11.7 1,075.0%  
Book value per share (Unadj.) Rs927.8372.3 249.2%  
Shares outstanding (eoy) m16.6070.38 23.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.71.4 335.5%   
Avg P/E ratio x39.6-65.3 -60.6%  
P/CF ratio (eoy) x32.839.9 82.1%  
Price / Book Value ratio x2.60.6 410.6%  
Dividend payout %717.9-110.2 -651.6%   
Avg Mkt Cap Rs m40,25716,680 241.4%   
No. of employees `0001.12.6 43.6%   
Total wages/salary Rs m1,3132,393 54.9%   
Avg. sales/employee Rs Th7,486.74,535.2 165.1%   
Avg. wages/employee Rs Th1,157.6919.8 125.9%   
Avg. net profit/employee Rs Th897.2-98.2 -913.6%   
INCOME DATA
Net Sales Rs m8,49011,801 71.9%  
Other income Rs m244984 24.8%   
Total revenues Rs m8,73412,785 68.3%   
Gross profit Rs m1,482-835 -177.5%  
Depreciation Rs m211674 31.3%   
Interest Rs m075 0.0%   
Profit before tax Rs m1,514-600 -252.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m660-   
Tax Rs m563-343 -163.8%   
Profit after tax Rs m1,017-256 -398.2%  
Gross profit margin %17.5-7.1 -246.7%  
Effective tax rate %37.157.3 64.9%   
Net profit margin %12.0-2.2 -553.4%  
BALANCE SHEET DATA
Current assets Rs m15,34320,384 75.3%   
Current liabilities Rs m1,9605,029 39.0%   
Net working cap to sales %157.6130.1 121.1%  
Current ratio x7.84.1 193.1%  
Inventory Days Days49105 46.5%  
Debtors Days Days28135 21.1%  
Net fixed assets Rs m1,2099,023 13.4%   
Share capital Rs m166141 117.9%   
"Free" reserves Rs m15,23526,058 58.5%   
Net worth Rs m15,40126,199 58.8%   
Long term debt Rs m00-   
Total assets Rs m17,59531,496 55.9%  
Interest coverage xNM-7.0-  
Debt to equity ratio x00-  
Sales to assets ratio x0.50.4 128.8%   
Return on assets %5.8-0.6 -1,010.0%  
Return on equity %6.6-1.0 -677.3%  
Return on capital %10.3-2.0 -513.1%  
Exports to sales %069.4 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA8,188 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,6368,188 20.0%   
Fx outflow Rs m4,368596 732.9%   
Net fx Rs m-2,7327,592 -36.0%   
CASH FLOW
From Operations Rs m-1,304-3,278 39.8%  
From Investments Rs m12,697-2,860 -443.9%  
From Financial Activity Rs m-301-24 1,241.7%  
Net Cashflow Rs m11,093-4,690 -236.5%  

Share Holding

Indian Promoters % 0.0 50.1 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 15.1 120.5%  
FIIs % 1.0 3.0 33.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 31.7 91.8%  
Shareholders   28,591 20,176 141.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   NATCO PHARMA  PANACEA BIOTECH  WOCKHARDT  ABBOTT INDIA  PLETHICO PHARMA  

Compare PROCTER & GAMBLE HEALTH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Falling Stocks, Tumbling Rupee and Weakening Economy(Podcast)

Another week of slowdown in the markets over fears of a looming slowdown in the domestic and global economy continue.

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

UNICHEM LAB Announces Quarterly Results (1QFY20); Net Profit Up 102.2% (Quarterly Result Update)

Jul 30, 2019 | Updated on Jul 30, 2019

For the quarter ended June 2019, UNICHEM LAB has posted a net profit of Rs 5 m (up 102.2% YoY). Sales on the other hand came in at Rs 2 bn (up 15.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB 2018-19 Annual Report Analysis (Annual Result Update)

Jul 4, 2019 | Updated on Jul 4, 2019

Here's an analysis of the annual report of UNICHEM LAB for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UNICHEM LAB. Also includes updates on the valuation of UNICHEM LAB.

UNICHEM LAB Announces Quarterly Results (4QFY19); Net Profit Up 31.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, UNICHEM LAB has posted a net profit of Rs 37 m (up 31.7% YoY). Sales on the other hand came in at Rs 3 bn (up 35.1% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

More Views on News

Most Popular

This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Interest Rates Are Low. Buy Solid Dividend Stocks Instead(The 5 Minute Wrapup)

Aug 13, 2019

The dividends paid by these stocks are helpful when interest rates are falling.

Smallcaps that Will Outperform in the Market Rebound(Profit Hunter)

Aug 12, 2019

Only These Smallcaps Will Give Historic Returns in the Future.

My Top 3 Dividend Stocks to Buy Now(Profit Hunter)

Aug 19, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Chandrayaan 2 Heads to the Moon and It's Good News for These Stocks(The 5 Minute Wrapup)

Aug 14, 2019

Why investors should take note of India's advantage as a low cost satellite launcher...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Aug 23, 2019 (Close)

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH 8-QTR ANALYSIS

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS